Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CVRx (CVRX) Change in Cash (2020 - 2026)

CVRx's quarterly Change in Cash came in at -$3.4 million in Q1 2026, down 4.29% year-on-year from -$3.6 million in Q1 2025, and up 63.84% quarter-over-quarter from -$9.4 million in Q4 2025.

CVRx has reported Change in Cash for 7 years, with the latest figure at -$3.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Cash fell 4.29% year-over-year to -$3.4 million; the trailing twelve-month figure through Mar 2026 stood at -$30.4 million (down 234.64% YoY), and the FY2025 full-year result was -$30.2 million, down 296.73% from the prior year.
  • Change in Cash for Q1 2026 stood at -$3.4 million, up from -$9.4 million in the prior quarter.
  • The five-year high for Change in Cash was $29.8 million in Q3 2024, with the low at -$12.5 million in Q2 2023.
  • Average Change in Cash over 5 years is -$4.1 million, with a median of -$7.8 million recorded in 2023.
  • Year-over-year, Change in Cash soared 480.48% in 2024 and plunged 263.13% in 2025.
  • Tracing CVRX's Change in Cash over 5 years: stood at -$3.8 million in 2022, then surged by 299.84% to $7.6 million in 2023, then retreated by 23.81% to $5.8 million in 2024, then sank by 263.13% to -$9.4 million in 2025, then surged by 63.84% to -$3.4 million in 2026.
  • The last three Change in Cash figures came in at -$3.4 million (Q1 2026), -$9.4 million (Q4 2025), and -$9.9 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -1.72 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -1.13 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -136.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -504.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -492.00 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 199.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.23 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 15.90 Mn
10 CVRx 144.43 Mn 72.13 Mn 12.88 Mn -3.41 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -3.41 Mn
Dec 31, 2025 -9.42 Mn
Sep 30, 2025 -9.90 Mn
Jun 30, 2025 -7.64 Mn
Mar 31, 2025 -3.27 Mn
Dec 31, 2024 5.77 Mn
Sep 30, 2024 29.76 Mn
Jun 30, 2024 -9.72 Mn
Mar 31, 2024 -10.45 Mn
Dec 31, 2023 7.58 Mn
Sep 30, 2023 -7.82 Mn
Jun 30, 2023 -12.46 Mn
Mar 31, 2023 -2.92 Mn
Dec 31, 2022 -3.79 Mn
Sep 30, 2022 -11.36 Mn
Jun 30, 2022 -9.83 Mn
Mar 31, 2022 -10.90 Mn
Dec 31, 2021 -28.84 Mn
Sep 30, 2021 123.79 Mn
Jun 30, 2021 -6.84 Mn
Mar 31, 2021 -5.14 Mn
Dec 31, 2020 -4.18 Mn
Sep 30, 2020 44.52 Mn